Zenas BioPharma grants stock options and RSUs to new hires as part of their inducement package under Nasdaq rules.
Quiver AI Summary
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced on November 16, 2026, the granting of non-qualified stock options and restricted stock units to newly hired employees as part of an inducement grant under Nasdaq rules. The total includes 225,000 stock options, exercisable at $27.93 each, and 9,000 restricted stock units. The stock options will vest over four years, while the restricted stock units will vest in four equal installments over the same period. Zenas is advancing key product candidates, including obexelimab, a monoclonal antibody targeting autoimmune diseases, and orelabrutinib, a selective oral BTK inhibitor for central nervous system conditions. The company aims to bring transformative therapies to patients and is committed to developing innovative solutions in the biopharmaceutical field.
Potential Positives
- The granting of non-qualified stock options and restricted stock units to new employees demonstrates Zenas BioPharma's commitment to attracting talent, which can enhance its innovation and development capabilities.
- The stock options and RSUs are directly tied to the company's performance, aligning employee interests with shareholder value, which may drive stronger company performance.
- The structure of the stock options and RSUs provides a long-term incentive for new employees, potentially leading to greater employee retention and stability within the company.
Potential Negatives
- The grant of stock options and restricted stock units may indicate that the company is struggling to attract talent without offering significant financial incentives, suggesting potential issues in its recruitment strategy.
- The large number of stock options and RSUs granted could raise concerns among investors about potential dilution of their shares, particularly if the company is not currently generating significant revenue.
- The use of inducement grants may suggest that Zenas is in a competitive job market or facing difficulties in retaining talent, which could impact its ability to execute its business strategy effectively.
FAQ
What are the recent stock options granted by Zenas BioPharma?
Zenas BioPharma granted 225,000 non-qualified stock options to new employees on November 16, 2026, as part of an inducement grant.
What is the exercise price for the stock options?
The exercise price for the stock options is $27.93, matching the closing price of Zenas’ common stock on the grant date.
How will the stock options vest for employees?
The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months.
What are restricted stock units (RSUs) granted by Zenas?
Zenas granted 9,000 RSUs, vesting in four equal installments over four years, tied to employees’ continued service with the company.
What is Zenas BioPharma's focus as a biopharmaceutical company?
Zenas BioPharma is focused on developing transformative therapies for autoimmune and inflammatory diseases, with a commitment to innovative treatment options.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZBIO Hedge Fund Activity
We have seen 91 institutional investors add shares of $ZBIO stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 6,500,520 shares (+407.9%) to their portfolio in Q3 2026, for an estimated $175,319,024
- ROYALTY PHARMA SUB-MANAGER, LLC added 2,388,150 shares (+inf%) to their portfolio in Q3 2026, for an estimated $64,408,405
- ENAVATE SCIENCES GP, LLC removed 1,000,000 shares (-25.5%) from their portfolio in Q3 2026, for an estimated $26,970,000
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 718,335 shares (-96.0%) from their portfolio in Q3 2026, for an estimated $19,373,494
- CANDRIAM S.C.A. added 654,833 shares (+inf%) to their portfolio in Q3 2026, for an estimated $17,660,846
- BLACKROCK, INC. added 646,493 shares (+24.1%) to their portfolio in Q3 2026, for an estimated $17,435,916
- BANK OF AMERICA CORP /DE/ removed 547,851 shares (-44.5%) from their portfolio in Q3 2026, for an estimated $14,775,541
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ZBIO Analyst Ratings
Wall Street analysts have issued reports on $ZBIO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/13/2026
- Citigroup issued a "Buy" rating on 09/30/2026
- Wedbush issued a "Outperform" rating on 09/30/2026
- Guggenheim issued a "Buy" rating on 08/14/2026
To track analyst ratings and price targets for $ZBIO, check out Quiver Quantitative's $ZBIO forecast page.
$ZBIO Price Targets
Multiple analysts have issued price targets for $ZBIO recently. We have seen 5 analysts offer price targets for $ZBIO in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $44.0 on 10/13/2026
- Yigal Nochomovitz from Citigroup set a target price of $48.0 on 09/30/2026
- Martin Fan from Wedbush set a target price of $45.0 on 09/30/2026
- Judah Frommer from Morgan Stanley set a target price of $32.0 on 08/14/2026
- Yatin Suneja from Guggenheim set a target price of $55.0 on 08/14/2026
Full Release
WALTHAM, Mass., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 225,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 9,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Stock Options have a ten-year term and an exercise price per share of $27.93, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of November 15, 2027, November 15, 2028, November 15, 2029 and November 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn .
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Contacts:
Investors:
Argot Partners
[email protected]
Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748